OBR Daily Commentary

forumImage

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

(MarketWatch) Dec 3, 2018 - Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced that data from the ECHELON-2 phase 3 clinical trial will be presented today in an oral session at the 60th American Society of Hematology (ASH) Annual Meeting.

Read Article arrow

William Harwin MD (Posted: December 05, 2018)

quotesLike the dataquotes

Add Comment 1 Comment
forumImage

Memorial Sloan Kettering to Offer DigniCap® Scalp Cooling Device in New York Metro Area Locations

(Yahoo! Finance) Feb 13, 2017 - Dignitana AB, the world leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was cleared in December 2015 by the U.S. FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, will be available at all Memorial Sloan Kettering Cancer Center (MSK) facilities that treat breast cancer.

Read Article arrow

William Harwin MD (Posted: February 15, 2017)

quotesAt Florida Cancer Specialists we have been using DigniCap for several months at 3 of our site and it does appear to be a real advance in preventing alopecia from chemotherapy. I just completed treatment with 6 cycles of TCH + Pertuzumab in a woman with breast cancer with a full head of hair at completion of treatment. The problems with DigniCap are the cost and lack of insurance reimbursement. It may not be fully effective in all patients especially with an Adriamycin regimen.quotes

Add Comment 1 Comment
forumImage

Using Generic Cancer Drug Could Save Many Millions of Dollars

(Johns Hopkins) Mar 15, 2016 - With the expiration in January of the patent on Gleevec, the drug that 15 years ago changed chronic myeloid leukemia (CML) from a death sentence to a treatable illness, insurance companies and patients have the opportunity to realize huge cost savings, new Johns Hopkins Bloomberg School of Public Health research suggests.

Read Article arrow

William Harwin MD (Posted: March 16, 2016)

quotesThe advent of generic Imatinib will present a conundrum for treating hematologist/oncologists. It is hard to argue with the potential cost savings but the NCCN guidelines. short of the difficult to obtain long term survival data, are clearly tilted towards the greater efficacy of Dasatinib and Nilotinib. Although starting with the generic medication may make the most sense from the cost and economic perspective, I am pretty sure most oncologists in the United States, if they themselves developed CML, would choose a 2nd generation TKI.quotes

Add Comment 4 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...